6:10 PM
 | 
Oct 24, 2013
 |  BC Extra  |  Clinical News

Rigel drops another program, moving forward with fostamatinib

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) discontinued development of R333 after twice-daily topical R333 missed the primary endpoint in the Phase II SKINDLE trial to treat discoid lupus erythematosus (DLE). The topical JAK kinase (JAK) and spleen tyrosine kinase (SYK) inhibitor did not improve the proportion of...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >